These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 4155234

  • 1. The clinical physiology of side effects in long-term L-DOPA therapy.
    Barbeau A.
    Adv Neurol; 1974; 5():347-365. PubMed ID: 4155234
    [No Abstract] [Full Text] [Related]

  • 2. [Long-term l-DOPA therapy for parkinsonism and its pathochemical aspect].
    Petelin LS, Vartanian KZ, Romenskaia LKh.
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1977; 77(12):1810-3. PubMed ID: 602554
    [Abstract] [Full Text] [Related]

  • 3. Peculiarities of L: -DOPA treatment of Parkinson's disease.
    Kostrzewa RM, Nowak P, Kostrzewa JP, Kostrzewa RA, Brus R.
    Amino Acids; 2005 Mar; 28(2):157-64. PubMed ID: 15750845
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [10 years of L-DOPA therapy of Parkinson's syndrome].
    Birkmayer W.
    Wien Klin Wochenschr; 1971 Apr 02; 83(13):221-7. PubMed ID: 4254333
    [No Abstract] [Full Text] [Related]

  • 6. Parkinson's disease--opportunities for novel therapeutics to reduce the problems of levodopa therapy.
    Fox SH, Chuang R, Brotchie JM.
    Prog Brain Res; 2008 Apr 02; 172():479-94. PubMed ID: 18772047
    [Abstract] [Full Text] [Related]

  • 7. The neuropharmacology of abnormal involuntary movement disorders (the dyskinesias).
    Marsden CD.
    Mod Trends Neurol; 1975 Apr 02; 6():141-66. PubMed ID: 127927
    [No Abstract] [Full Text] [Related]

  • 8. Dopaminergic supersensitivity in parkinsonism.
    Birkmayer W, Danielczyk W, Neumayer E, Riederer P.
    Adv Neurol; 1975 Apr 02; 9():121-9. PubMed ID: 1146650
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Serotonin-dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias.
    Carta M, Carlsson T, Muñoz A, Kirik D, Björklund A.
    Prog Brain Res; 2008 Apr 02; 172():465-78. PubMed ID: 18772046
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Biochemical neuropathology of Parkinson's disease.
    Javoy-Agid F, Ruberg M, Taquet H, Bokobza B, Agid Y, Gaspar P, Berger B, N'Guyen-Legros J, Alvarez C, Gray F.
    Adv Neurol; 1984 Apr 02; 40():189-98. PubMed ID: 6695594
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Effect of L-DOPA on the synthesis and excretion of tyramine.
    Boulton AA, Wu PH.
    Adv Neurol; 1974 Apr 02; 5():119-25. PubMed ID: 4613157
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Biochemical evaluation of the effectiveness of antiparkinson preparations containing L-DOPA].
    Vartanian KZ.
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1981 Apr 02; 81(12):1777-81. PubMed ID: 6803476
    [Abstract] [Full Text] [Related]

  • 18. L-dopa-induced peak-dose dyskinesias in patients with Parkinson's disease: a clinical pharmacologic approach.
    Rascol O.
    Mov Disord; 1999 Apr 02; 14 Suppl 1():19-32. PubMed ID: 10493400
    [No Abstract] [Full Text] [Related]

  • 19. Accuracy of acute levodopa challenge for clinical prediction of sustained long-term levodopa response as a major criterion for idiopathic Parkinson's disease diagnosis.
    Merello M, Nouzeilles MI, Arce GP, Leiguarda R.
    Mov Disord; 2002 Jul 02; 17(4):795-8. PubMed ID: 12210878
    [Abstract] [Full Text] [Related]

  • 20. Levodopa in Parkinsonism.
    Weiss JL, Chase TN.
    Drugs; 1971 Jul 02; 2(4):257-61. PubMed ID: 4948349
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.